$WAT

Waters (WAT) After Fresh Guidance And Earnings Update Is The Valuation Case Still Intact

Waters (WAT) issued new Q3 and full-year 2026 revenue guidance and reported Q2 results showing higher sales but a shift to a net loss, according to the company. The article cites a 90-day return of 14.57% and 1-year total shareholder return of 44.69%. It discusses valuation versus a $413.26 fair value estimate and notes recurring revenue up 11% this quarter.

Original reporting
Published Aug 8, 2026, 5:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 8, 2026, 10:05 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$WAT
Neutral
medium confidence
Mentioned
$WAT
Relevance
6/10
alphai data visualization · based on simplywall.st
Decision brief

The 30-second read

$WATNeutralMed
01

Why it matters

Traders can reassess whether the market’s implied growth and margin path is consistent with the new Q3 and full-year 2026 guidance, especially given the reported shift to net loss in Q2.

02

Market read

The article centers on whether fair value remains intact after guidance and earnings, using price versus fair value and P/S multiple comparisons.

03

What to watch

Integration risk around BD businesses and potential tariff or trade-policy margin pressure are flagged, but the article does not quantify their magnitude or timing.

Relevance 6/10Novelty 5/10Timing: post-guidance and post-earnings update

Background

The piece frames Waters’ recent stock run and then focuses on the latest guidance and earnings update as the driver of the current valuation debate.

Company-level read

Ticker impact

$WATNeutralMedium confidence
Context

Waters issued new Q3 and full-year 2026 revenue guidance alongside Q2 results showing higher sales and a shift to net loss.

Expected impact

Near-term volatility likely as traders weigh guidance credibility versus the net-loss shift and valuation gap to fair value.

Evidence & confidence

The article provides specific guidance and earnings direction (higher sales, net loss) plus valuation framing (price vs fair value, P/S vs peers), but it is still an analysis piece rather than a primary filing or transcript.

Market effects

Signals ongoing demand and recurring-revenue emphasis in lab equipment and services, but highlights tariff/trade-policy sensitivity for margins.

No specific regional impact described.

No explicit global macro or cross-border regulatory catalyst described.

Counterpoint

The valuation support is largely model-driven (DCF and multiple assumptions). If the net-loss shift reflects structural margin pressure, the “undervalued” narrative may be overstated.

Key entities

  • Waters

    Subject of the article, with new Q3 and full-year 2026 revenue guidance and Q2 results showing higher sales and a shift to net loss.

Related articles

$WATHighAI 9/10

Waters (WAT) Q2 2026 Earnings Call Transcript

Waters (WAT) reported Q2 2026 revenue of $1.645 billion, above the top of guidance, with 9% organic growth and adjusted EPS of $3.05. Full-year 2026 guidance was raised to 7% to 9% organic revenue growth and adjusted EPS of $14.45 to $14.65. Management cited cost actions, FX headwinds, China DRG headwinds, and progress in acquired biosciences and diagnostics.

$WATMedAI 8/10

Waters Q2 Earnings Call Highlights

Waters (NYSE:WAT) reported Q2 updates from its earnings call. Materials Science Division revenue rose to $87M. Biosciences and Diagnostic Solutions acquired from BD generated $817M revenue. Waters raised FY organic constant-currency growth outlook to 7% to 9%, projecting FY reported revenue of $3.370B to $3.431B and adjusted EPS of $14.45 to $14.65.

$WATMedAI 8/10

Waters Corporation Q2 2026 Earnings Call Summary

Waters Corp reported 9% organic constant-currency growth in Q2 2026, citing strength in pharma and academic end markets and a 400 bps growth acceleration in newly acquired Biosciences and Diagnostic Solutions. The company raised 2026 organic revenue guidance to 7-9%, expects acquired businesses to exit 2026 at 6%+ growth, and projects mid-teens adjusted EPS growth with margin expansion.

$WATHighAI 8/10

Why Waters Corporation (WAT) Stock Is Trading Up Today

Waters Corp (NYSE:WAT) shares rose about 5% after the company reported Q2 results that beat Wall Street and lifted full-year guidance. Waters posted adjusted EPS of $3.05 on revenue of $1.65B, with 7% organic growth. The company now expects 2026 adjusted earnings around $14.55 per share at the midpoint.